| 1987 |
Founded in Numazu City, Shizuoka Prefecture, to conduct research and development of in vitro diagnostic pharmaceuticals, research reagents, and various analytical reagents, as well as development of related systems. |
| 1987 |
Established a Tokyo branch and commenced sales. |
| 1994 |
Constructed a new headquarters building in Kozu, Numazu City, Shizuoka Prefecture. |
| 2001 |
Built a new diagnostic drug factory, "Numazu Factory", in Kozu, Numazu City, Shizuoka Prefecture. |
| 2002 |
Spin-off the development division into BL Corporation. |
| 2007 |
Obtained a patent for the platinum-gold colloid manufacturing method. |
| 2007 |
Constructed a new headquarters building in Futaba-cho, Numazu City, Shizuoka Prefecture. |
| 2007 |
Obtained platinum-gold colloid manufacturing patent. Built new headquarters in Futaba Town, Numazu City, Shizuoka Prefecture. |
| 2008 |
Manufactured and sold diagnostic kits "Capilia® O157" for Escherichia coli O157 infection and "Capilia® VT" for hemorrhagic colitis caused by E. coli. |
| 2008 |
Launched the world's first rapid diagnostic kit "ImunoEase® Adeno" using platinum-gold colloid for adenovirus infection. |
| 2008 |
Launched the rapid diagnostic kit "ImunoEase® Flu" for influenza virus infection. |
| 2008 |
Manufactured and sold diagnostic kits for E. coli O157 infection, 'Capilia® O157', and enterohemorrhagic E. coli infection, 'Capilia® VT'. Launched the world's first rapid diagnostic kit for adenovirus infection using platinum-gold colloid, 'ImnoAce® Adeno'. Launched rapid diagnostic kit for influenza virus infection, 'ImnoAce® Flu'. |
| 2010 |
Launched research reagent "LineJudge® FluA/pdm". |
| 2011 |
Launched diagnostic kit "Capilia® MAC Antibody ELISA" for pulmonary MAC disease. |
| 2012 |
Established "Kami-shima Factory" in Kami-shima, Izu-no-kuni City, Shizuoka Prefecture. |
| 2012 |
Launched diagnostic kit "Capilia® TB-Neo" for tuberculosis. |
| 2012 |
Relocated headquarters to Kamijima, Izu, Shizuoka Prefecture. |
| 2012 |
Obtained ISO13485 certification. |
| 2012 |
Launched rapid diagnostic kit for RS virus infection, 'ImnoAce® RSV Neo'. |
| 2012 |
Established the "Kami-shima Factory" in Kami-shima, Izunokuni City, Shizuoka Prefecture. Launched the tuberculosis diagnostic kit "Capilia® TB-Neo". Moved headquarters to Kami-shima, Izunokuni City, Shizuoka Prefecture. Acquired ISO13485 certification. Launched the rapid diagnostic kit for RS virus infection "ImnoAce® RSV Neo". |
| 2013 |
Launched rapid diagnostic kit for Group A streptococcal infection, 'ImnoAce® Strep A'. |
| 2015 |
Launched rapid diagnostic kit for Mycoplasma infection, 'ImnoAce® Mycoplasma'. |
| 2016 |
Launched rapid diagnostic kit for Human Metapneumovirus infection, 'ImnoAce® hMPV'. |
| 2016 |
Merged with B.L. Corporation and integrated development departments. |
| 2016 |
Launched the rapid diagnostic kit for Human Metapneumovirus infection "ImnoAce® hMPV". Merged with B.L. Corporation and integrated the development division. |
| 2020 |
Launched rapid diagnostic kit for influenza virus and/or RS virus infection, 'ImnoAce® Flu/RSV'. |
| 2020 |
Established Shimizu Town Office and R&D Center in Shimizu Town, Sunto District, Shizuoka Prefecture. |
| 2020 |
Launched rapid diagnostic kit for Group A streptococcal infection, 'ImnoAce® Strep A Neo'. |
| 2020 |
Launched rapid diagnostic kit for SARS-CoV-2 infection, 'ImnoAce® SARS-CoV-2'. |
| 2020 |
Launched rapid diagnostic kit for Norovirus infection, 'ImnoAce® Noro'. |
| 2020 |
Launched the rapid diagnostic kit for influenza virus and/or RS virus infection "ImnoAce® Flu/RSV". Established Shimizu Town Office & R&D Center in Shimizu Town, Sunto District, Shizuoka Prefecture. Launched the rapid diagnostic kit for Group A streptococcal infection "ImnoAce® Strep A Neo". Launched the rapid diagnostic kit for SARS-CoV-2 infection "ImnoAce® SARS-CoV-2". Launched the rapid diagnostic kit for Norovirus infection "ImnoAce® Noro". |
| 2021 |
Launched rapid diagnostic kit for SARS-CoV-2 infection, 'ImnoAce® SARS-CoV-2 II'. |
| 2021 |
Launched the rapid diagnostic kit for SARS-CoV-2 infection "ImnoAce® SARS-CoV-2 II". |
| 2022 |
Launched rapid diagnostic kit for SARS-CoV-2 infection, 'ImnoAce® SARS-CoV-2 Saliva'. |
| 2022 |
Launched rapid diagnostic kit for SARS-CoV-2 and/or influenza virus infection, 'ImnoAce® SARS-CoV-2/Flu'. |
| 2022 |
Launched the rapid diagnostic kit for SARS-CoV-2 infection "ImnoAce® SARS-CoV-2 Saliva". Launched the rapid diagnostic kit for SARS-CoV-2 or influenza virus infection "ImnoAce® SARS-CoV-2/Flu". |
| 2023 |
Developed (and sold by Nobel Pharma Inc.) zinc kit 'Acuride Zinc' and general spectrophotometry analyzer 'Acuride'. |
| 2024 |
Launched rapid diagnostic kit for SARS-CoV-2 infection, 'ImnoAce® SARS-CoV-2 III'. |
| 2024 |
Listed on the Tokyo Stock Exchange Standard Market. |
| 2024 |
Launched the rapid diagnostic kit for SARS-CoV-2 infection "ImnoAce® SARS-CoV-2 III". Listed on the Tokyo Stock Exchange Standard Market. |
